Sales of research products and services in the first quarter of 2011 were $3.1 million, down 24% compared to the prior year period due to continued weakness in pharmaceutical outsourcing.
First quarter product sales were ($ in millions):Three Months Ended March 31,Change2011
-5%Research Products and Services
-25%Total Product Sales
+6%Collaborative research revenues in the first quarter of 2011 were $3.6 million, compared to $3.3 million in the prior year period, an increase of 9% that resulted primarily from increased funding from Novartis associated with the development of the fully automated PANTHER™ instrument and the PROCLEIX® ULTRIO® Plus assay for the blood screening market.
Royalty and license revenues in the first quarter of 2011 were $1.4 million, compared to $1.6 million in the prior year period, a decrease of 13% that resulted from the combined effect of several small items.
GAAP Income Statement DetailsGross margin on product sales was 69.6% in the first quarter of 2011, compared to 67.3% in the prior year period. This increase resulted mainly from a favorable product sales mix, namely higher sales of PRODESSE and APTIMA products, and lower sales of instrumentation.
Acquisition-related amortization expenses were $2.8 million in the first quarter of 2011, compared to $2.2 million in the prior year period, an increase of 27% that resulted mainly from the acquisition of GTI in December of 2010.
Research and development (R&am
|SOURCE Gen-Probe Incorporated|
Copyright©2010 PR Newswire.
All rights reserved